The Association between Antidiabetic Agents and Leukocyte Telomere Length in the Novel Classification of Type 2 Diabetes Mellitus
The Association between Antidiabetic Agents and Leukocyte Telomere Length in the Novel Classification of Type 2 Diabetes Mellitus
复制标题
DOI：
10.1159/000511362
复制
发表时间：
2020-12-15
期刊：
影响因子：
3.5
通讯作者：
Yang, Yan
中科院分区：
文献类型：
--
作者：
Huang, Jiaojiao;Peng, Xuemin;Yang, Yan
目的：本研究旨在探讨端粒长度（TL）在聚类分析驱动的2型糖尿病（T2 DM）新分类中的新作用。材料与方法：通过k均值分析将541例T2 DM患者分为4个亚组：轻度肥胖相关糖尿病（MOD）、重度胰岛素缺乏型糖尿病（SIDD）、重度胰岛素抵抗型糖尿病（SIRD）和轻度年龄相关糖尿病（MARD）。排除数据不充分的患者后，对246例T2 DM患者进行进一步分析。采用端粒限制性片段法检测TL，并按临床标准程序测定相关糖尿病指标。结果：MARD组的TL显著短于MOD组和SIDD组。然后，我们将所有T2 DM患者分为MARD和NONMARD组，包括MOD、SIDD和SIRD组。发现MARD组的TL与年龄相关，显著短于NONMARD组（p = 0.0012），二甲双胍（p = 0.880）和阿卡波糖（p = 0.058）治疗后，TL的这种差异消失。线性分析显示二甲双胍能更明显地减少MARD组的端粒缩短（r = 0.030，95%CI 0.010-0.051，p = 0.004），阿卡波糖能更明显地促进SIRD组端粒的磨损（r =-0.069，95%CI-0.100至-0.039，p < 0.001）与其他T2 DM患者相比。结论：发现MARD组的TL较短，二甲双胍的抗衰老作用比其他T2 DM受益更多。阿卡波糖使用后，SIRD组中观察到较短的TL。
Aims: This study aimed to explore the new role of telomere length (TL) in the novel classification of type 2 diabetes mellitus (T2DM) patients driven by cluster analysis. Materials and Methods: A total of 541 T2DM patients were divided into 4 subgroups by k-means analysis: mild obesity-related diabetes (MOD), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), and mild age-related diabetes (MARD). After patients with insufficient data were excluded, further analysis was conducted on 246 T2DM patients. The TL was detected using telomere restriction fragment, and the related diabetic indexes were also measured by clinical standard procedures. Results: The MARD group had significantly shorter TLs than the MOD and SIDD groups. Then, we subdivided all T2DM patients into the MARD and NONMARD groups, which included the MOD, SIDD, and SIRD groups. The TLs of the MARD group, associated with age, were discovered to be significantly shorter than those of the NONMARD group (p = 0.0012), and this difference in TL disappeared after metformin (p = 0.880) and acarbose treatment (p = 0.058). The linear analysis showed that metformin can more obviously reduce telomere shortening in the MARD group (r = 0.030, 95% CI 0.010-0.051, p = 0.004), and acarbose can more apparently promote telomere attrition in the SIRD group (r = -0.069, 95% CI -0.100 to -0.039, p< 0.001) compared with other T2DM patients after adjusting for age and gender. Conclusions: The MARD group was found to have shorter TLs and benefit more from the antiaging effect of metformin than other T2DM. Shorter TLs were observed in the SIRD group after acarbose use.